MA53909B1 - Compositions et méthodes de stimulation ovarienne contrôlée - Google Patents
Compositions et méthodes de stimulation ovarienne contrôléeInfo
- Publication number
- MA53909B1 MA53909B1 MA53909A MA53909A MA53909B1 MA 53909 B1 MA53909 B1 MA 53909B1 MA 53909 A MA53909 A MA 53909A MA 53909 A MA53909 A MA 53909A MA 53909 B1 MA53909 B1 MA 53909B1
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methods
- ovarian stimulation
- controlled ovarian
- controlled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pregnancy & Childbirth (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des méthodes et des compositions faisant intervenir de la FSH pour une utilisation dans le traitement de l'infertilité, la dose étant sélectionnée sur la base de l'âge du patient pour optimiser l'efficacité cumulative et/ou réduire le risque d'OHSS.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746812P | 2018-10-17 | 2018-10-17 | |
| EP18203167 | 2018-10-29 | ||
| EP19794444.0A EP3866833B1 (fr) | 2018-10-17 | 2019-10-17 | Compositions comprenant de la fsh recombinante pour le traitement de l'infertilité |
| PCT/EP2019/078170 WO2020079127A1 (fr) | 2018-10-17 | 2019-10-17 | Compositions et méthodes de stimulation ovarienne contrôlée |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53909A MA53909A (fr) | 2022-01-26 |
| MA53909B1 true MA53909B1 (fr) | 2025-07-31 |
Family
ID=68344788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53909A MA53909B1 (fr) | 2018-10-17 | 2019-10-17 | Compositions et méthodes de stimulation ovarienne contrôlée |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US12311012B2 (fr) |
| EP (2) | EP3866833B1 (fr) |
| JP (2) | JP7555915B2 (fr) |
| KR (1) | KR20210079276A (fr) |
| CN (1) | CN112789053A (fr) |
| AU (1) | AU2019363279B2 (fr) |
| BR (1) | BR112021005019A2 (fr) |
| CA (1) | CA3110205A1 (fr) |
| CL (2) | CL2021000928A1 (fr) |
| CO (1) | CO2021005872A2 (fr) |
| DK (1) | DK3866833T3 (fr) |
| ES (1) | ES3026229T3 (fr) |
| FI (1) | FI3866833T3 (fr) |
| HR (1) | HRP20250463T1 (fr) |
| HU (1) | HUE070973T2 (fr) |
| IL (1) | IL280750A (fr) |
| JO (1) | JOP20210025B1 (fr) |
| LT (1) | LT3866833T (fr) |
| MA (1) | MA53909B1 (fr) |
| MD (1) | MD3866833T2 (fr) |
| MX (1) | MX2021004383A (fr) |
| MY (1) | MY210133A (fr) |
| PH (1) | PH12021550417A1 (fr) |
| PL (1) | PL3866833T3 (fr) |
| RS (1) | RS66713B1 (fr) |
| SG (1) | SG11202102340RA (fr) |
| SI (1) | SI3866833T1 (fr) |
| TW (1) | TWI846743B (fr) |
| UA (1) | UA128731C2 (fr) |
| WO (1) | WO2020079127A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020002235A (es) | 2017-09-01 | 2020-07-20 | Ferring Bv | Composicion para la estimulacion ovarica controlada. |
| TW202237173A (zh) * | 2020-12-09 | 2022-10-01 | 荷蘭商菲林公司 | 用於受控的卵巢刺激之組成物及方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04002257A (es) * | 2001-09-12 | 2004-07-23 | Applied Research Systems | Uso de gonadotropina corionica humana (gch) y su hormona de liberacion (hl) en hiperestimulacion ovarica controlada. |
| EP1364658A1 (fr) * | 2002-05-24 | 2003-11-26 | Applied Research Systems ARS Holding N.V. | Utilisation de rapports variables de gonadotrophines dans l'hyperstimulation ovarienne contrôlée |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| EP2717904A1 (fr) | 2011-06-06 | 2014-04-16 | Ferring BV | Préparation pharmaceutique |
| JO3092B1 (ar) * | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| EP2956542A4 (fr) | 2013-02-15 | 2016-09-14 | Sungkwang Medical Foundation | Production de cellules souches parthénogénétiques et de cellules souches embryonnaires humaines spécifiques d'un patient par transfert nucléaire de cellules somatiques |
| EP3283097B1 (fr) | 2015-04-17 | 2020-02-12 | Ferring B.V. | Fsh pour le traitement de l'infertilité |
| MX2020002235A (es) | 2017-09-01 | 2020-07-20 | Ferring Bv | Composicion para la estimulacion ovarica controlada. |
| HUE071268T2 (hu) | 2018-04-30 | 2025-08-28 | Ferring Bv | Készítmény szabályozott petefészek-stimuláláshoz |
| TW202237173A (zh) | 2020-12-09 | 2022-10-01 | 荷蘭商菲林公司 | 用於受控的卵巢刺激之組成物及方法 |
-
2019
- 2019-10-16 TW TW108137295A patent/TWI846743B/zh active
- 2019-10-17 MX MX2021004383A patent/MX2021004383A/es unknown
- 2019-10-17 CA CA3110205A patent/CA3110205A1/fr active Pending
- 2019-10-17 BR BR112021005019-1A patent/BR112021005019A2/pt unknown
- 2019-10-17 RS RS20250371A patent/RS66713B1/sr unknown
- 2019-10-17 CN CN201980064065.3A patent/CN112789053A/zh active Pending
- 2019-10-17 HU HUE19794444A patent/HUE070973T2/hu unknown
- 2019-10-17 KR KR1020217008853A patent/KR20210079276A/ko not_active Ceased
- 2019-10-17 ES ES19794444T patent/ES3026229T3/es active Active
- 2019-10-17 WO PCT/EP2019/078170 patent/WO2020079127A1/fr not_active Ceased
- 2019-10-17 HR HRP20250463TT patent/HRP20250463T1/hr unknown
- 2019-10-17 PL PL19794444.0T patent/PL3866833T3/pl unknown
- 2019-10-17 US US17/285,314 patent/US12311012B2/en active Active
- 2019-10-17 MA MA53909A patent/MA53909B1/fr unknown
- 2019-10-17 MD MDE20210789T patent/MD3866833T2/ro unknown
- 2019-10-17 SG SG11202102340RA patent/SG11202102340RA/en unknown
- 2019-10-17 SI SI201930926T patent/SI3866833T1/sl unknown
- 2019-10-17 UA UAA202102528A patent/UA128731C2/uk unknown
- 2019-10-17 LT LTEPPCT/EP2019/078170T patent/LT3866833T/lt unknown
- 2019-10-17 AU AU2019363279A patent/AU2019363279B2/en active Active
- 2019-10-17 FI FIEP19794444.0T patent/FI3866833T3/fi active
- 2019-10-17 EP EP19794444.0A patent/EP3866833B1/fr active Active
- 2019-10-17 MY MYPI2021002006A patent/MY210133A/en unknown
- 2019-10-17 EP EP25150679.6A patent/EP4516354A3/fr active Pending
- 2019-10-17 JP JP2021521140A patent/JP7555915B2/ja active Active
- 2019-10-17 DK DK19794444.0T patent/DK3866833T3/da active
-
2021
- 2021-02-07 JO JOJO/P/2021/0025A patent/JOP20210025B1/ar active
- 2021-02-09 IL IL280750A patent/IL280750A/en unknown
- 2021-02-26 PH PH12021550417A patent/PH12021550417A1/en unknown
- 2021-04-15 CL CL2021000928A patent/CL2021000928A1/es unknown
- 2021-05-04 CO CONC2021/0005872A patent/CO2021005872A2/es unknown
-
2022
- 2022-03-29 CL CL2022000779A patent/CL2022000779A1/es unknown
-
2024
- 2024-06-24 JP JP2024100990A patent/JP2024133520A/ja active Pending
-
2025
- 2025-05-06 US US19/200,288 patent/US20250325637A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| PH12020551427A1 (en) | Epinephrine spray formulations | |
| MX2018015684A (es) | Composiciones y metodos para el agotamiento de celulas cd117. | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2021004755A (es) | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria. | |
| MX2019008124A (es) | Metodos para el tratamiento de trastornos neurologicos. | |
| JOP20210245A1 (ar) | طرق لعلاج الداء النشواني من النوع خفيف السلسلة | |
| PH12019550265A1 (en) | Composition comprising mannose oligosaccharide and process for making same and use thereof | |
| NZ762312A (en) | Anti-pacap antibody | |
| MX2025013942A (es) | Anticuerpos contra mucina 16 y metodos de uso de los mismos | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| PH12021550122A1 (en) | Solubilized apyrases, methods and use | |
| MX2024002069A (es) | Anticuerpos anti-hla-g. | |
| MA53909B1 (fr) | Compositions et méthodes de stimulation ovarienne contrôlée | |
| ZA202002107B (en) | Use of specific sirna against protein s for the treatment of hemophilia | |
| MX2022005032A (es) | Terapia secuencial anti cumulo de diferenciacion 19 (cd19). | |
| WO2019190927A3 (fr) | Oligonucléotides à permutation d'épissage et méthodes d'utilisation | |
| CA3091759A1 (fr) | Procedes et compositions pour maintenir l'efficacite des opioides dans le traitement de la douleur | |
| MX2020012805A (es) | Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos. | |
| MX2020013103A (es) | Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia. | |
| PH12020500404A1 (en) | Composition for controlled ovarian stimulation | |
| MX2025015454A (es) | Formulaciones/composiciones que comprenden ibrutinib | |
| GEP20207136B (en) | Antiseptic composition comprising polyvinylpyrrolidone and unithiol and use of the composition | |
| EA202190891A1 (ru) | Композиции и способы для контролируемой стимуляции яичников |